Particle size analysis of nanocrystals: Improved analysis method

International Journal of Pharmaceutics

Volumn 390, Issue 1, 2010, Pages 3-12

  Keck, C M ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Dissolution; Laser diffraction; Nanocrystals; Nanoparticles; Nanosuspensions; Optical parameters; Optimized sizing method; Particle size; Refractive index

Indexed keywords

CYCLOSPORIN; DODECYL SULFATE SODIUM; NANOCRYSTAL; POLOXAMER; POLYOXYETHYLENE; POLYSORBATE 80; RUTOSIDE; TOCOFERSOLAN; ALPHA TOCOPHEROL; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; EXCIPIENT; MACROGOL DERIVATIVE; NANOPARTICLE; POLYSORBATE;

ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISPERSION; DISSOLUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; INTERMETHOD COMPARISON; LASER DIFFRACTION; LIGHT SCATTERING; MICROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; REPRODUCIBILITY; STORAGE TEMPERATURE; SUSPENSION; ANALOGS AND DERIVATIVES; CHEMICAL ANALYSIS; CHEMISTRY; DEVICES; LIGHT; PROCEDURES; RADIATION SCATTERING; REFRACTOMETRY; SMALL ANGLE SCATTERING; SOLUBILITY; TEMPERATURE;

CHEMISTRY TECHNIQUES, ANALYTICAL; CYCLOSPORINE; DRUG STABILITY; EXCIPIENTS; LIGHT; MICROSCOPY; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; POLYETHYLENE GLYCOLS; POLYSORBATES; REFRACTOMETRY; RUTIN; SCATTERING, RADIATION; SCATTERING, SMALL ANGLE; SODIUM DODECYL SULFATE; SOLUBILITY; TEMPERATURE; VITAMIN E;

EID: 77951259002     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.08.042     Document Type: Article

References (25)

1. Bott, S.E., Hart, W.H., 1990. Particle size analysis utilizing polarization intensity differential scattering. United States Patent 4,953,978.
2. Carl Englert B. Nanomaterials and the environment: uses, methods and measurement. J. Environ. Monit. 2007, 9:1154-1161.
3. ISO13320-1, International Organization of Standardization, 1999. Particle size analysis-laser diffraction methods. Part 1. General principles.
4. ISO-14488, International Organization of Standardization, 2000. Particulate materials-sampling and sample splitting for the determination of particulate properties.
5. ISO/TS-27687, International Organization of Standardization, 2008. Nanotechnologies - terminology and definitions for nanoobjects - nanoparticle, nanofibre and nanoplate.
6. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 2006, 111:56-64.
7. Keck C., Müller R.H. Size Analysis by Laser Diffractometry-How Valid are the Data? 2004, AAPS, Baltimore.
8. Keck C., Müller R.H. Characterisation of Nanosuspensions by Laser Diffractometry 2005, AAPS, Nashville.
9. Keck C., Müller R.H. Particle Size Analysis with Laser Diffractometry is not Sensitive Enough to Detect Changes in a Lipid Carrier System 2005, AAPS, Nashville.
10. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
11. Keck C.M., Müller R.H. Size analysis of submicron particles by laser diffractometry-90% of the published measurements are false. Int. J. Pharm. 2008, 355:150-163.
12. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47:65-81.
13. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
14. Müller R.H. Nanosuspensionen-Eine neue Formulierung für Schwerlösliche Arzneistoffe 1998, 393-400. Pharmazeutische Technologie: Moderne Arzneiformen Wissenschaftliche Verlagsgesellschaft, Stuttgart. R.H. Müller, G.E. Hildebrand (Eds.).
15. Müller, R.H., Becker, R., Kruss, B., Peters, K., 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States Patent 5,858,410.
16. Müller R.H., Junghanns J.-U. Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs. Nanoparticulates as Drug Carriers 2006, 307-328. Imperial College Press, London. V.P. Torchilin (Ed.).
17. PAS71, 2005. Publicly Available Specification from The British Standards Institution (BSI).
18. Patravale V.B., Date A.A., Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004, 56:827-840.
19. Prosie F., Lesage F.X., Deschamps F. Nanoparticles: structures, utilizations and health impacts. Presse Med. 2008, 37:1431-1437.
20. Rao G.C., Kumar M.S., Mathivanan N., Rao M.E. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004, 59:5-9.
21. Rawle A. Nanopowders-An Oxymoron? (March 9). Particles 2004-Particle Synthesis, Characterization, and Particle-Based Advanced Materials Orlando 2004.
22. Rawle, A., 2007. Verification aspects of validation for particle size analysis methods. Annual Meeting of Pharmaceutical Scientists (AAPS). San Diego, 15th November.
23. Stegemann S., Leveiller F., Franchi D., de Jong H., Linden H. When poor solubility becomes an issue: from early stage to proof of concept. Eur. J. Pharm. Sci. 2007, 31:249-261.
24. Warheit D.B., Sayes C.M., Reed K.L., Swain K.A. Health effects related to nanoparticle exposures: environmental, health and safety considerations for assessing hazards and risks. Pharmacol. Ther. 2008, 120:35-42.
25. Xu, R., 2003. Extracted polarization intensity differential scattering for particle characterization. United States Patent 6,859,276.